-
公开(公告)号:US07863445B2
公开(公告)日:2011-01-04
申请号:US12542050
申请日:2009-08-17
申请人: Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Stefan Muller , Ernst Baumann , Joachim Rheinheimer , Uwe Josef Vogelbacher , Wolfgang Wernet , Liliane Unger , Manfred Raschack
发明人: Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Stefan Muller , Ernst Baumann , Joachim Rheinheimer , Uwe Josef Vogelbacher , Wolfgang Wernet , Liliane Unger , Manfred Raschack
IPC分类号: C07D239/02
CPC分类号: C07D495/04 , C07D239/34 , C07D239/48 , C07D239/52 , C07D239/60 , C07D239/70 , C07D239/96 , C07D251/20 , C07D251/26 , C07D251/52 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D491/04 , C07D491/048
摘要: Carboxylic acid derivatives where R-R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.
-
72.Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor 有权
标题翻译: 苯磺酰苯胺化合物适用于治疗对血清素5-HT6受体调节作用的疾病公开(公告)号:US07790727B2
公开(公告)日:2010-09-07
申请号:US12262455
申请日:2008-10-31
申请人: Wilfried Martin Braje , Sean Colm Turner , Andreas Haupt , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Wolfgang Wernet , Matthias Mayrer , Ana Jongen-Relo , Anton Bespalov , Min Zhang
发明人: Wilfried Martin Braje , Sean Colm Turner , Andreas Haupt , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Wolfgang Wernet , Matthias Mayrer , Ana Jongen-Relo , Anton Bespalov , Min Zhang
IPC分类号: A61K31/495 , A61K31/496 , C07D295/135 , C07D317/62
CPC分类号: C07D295/12 , C07D405/12
摘要: The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R1 is hydrogen or methyl R2 is hydrogen or methyl R3 hydrogen, fluorine C1-C2 alkoxy or fluorinated C1-C2 alkoxy; R4 is hydrogen, C1-C4 alkyl or fluorinated C1-C4 alkyl; R5 is hydrogen, fluorine, C1-C2 alkyl, fluorinated C1-C2 alkyl, C1-C2 alkoxy or fluorinated C1-C2 alkoxy; and R6 is hydrogen, fluorine or chlorine.
摘要翻译: 本发明涉及式I和I'的新型苯磺酰苯胺化合物和生理上耐受的酸加成盐及其N-氧化物。 该化合物具有有价值的治疗特性,特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。 其中R1是氢或甲基R2是氢或甲基R3氢,氟C1-C2烷氧基或氟化C1-C2烷氧基; R4是氢,C1-C4烷基或氟化C1-C4烷基; R5是氢,氟,C1-C2烷基,氟化C1-C2烷基,C1-C2烷氧基或氟化C1-C2烷氧基; R6是氢,氟或氯。
-
公开(公告)号:US07119097B2
公开(公告)日:2006-10-10
申请号:US11377879
申请日:2006-03-16
申请人: Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Stefan Muller , Ernst Baumann , Joachim Rheinheimer , Uwe Josef Vogelbacher , Wolfgang Wernet , Liliane Unger , Manfred Raschack
发明人: Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Stefan Muller , Ernst Baumann , Joachim Rheinheimer , Uwe Josef Vogelbacher , Wolfgang Wernet , Liliane Unger , Manfred Raschack
IPC分类号: C07D239/60 , C07D403/12 , C07D251/30 , C07D239/96 , A61K31/505
CPC分类号: C07D495/04 , C07D239/34 , C07D239/48 , C07D239/52 , C07D239/60 , C07D239/70 , C07D239/96 , C07D251/20 , C07D251/26 , C07D251/52 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D491/04 , C07D491/048
摘要: A compound of the formula pharmaceutically acceptable salts and enantiomers thereof and pharmaceutical compositions containing this compound, its pharmaceutically acceptable salts and enantiomers are claimed.
摘要翻译: 本发明要求具有下式的化合物,其药学上可接受的盐和对映体以及含有该化合物,其药学上可接受的盐和对映体的药物组合物。
-
公开(公告)号:US20060160808A1
公开(公告)日:2006-07-20
申请号:US11377879
申请日:2006-03-16
申请人: Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Stefan Muller , Ernst Baumann , Joachim Rheinheimer , Owe Vogelbacher , Wolfgang Wernet , Liliane Unger , Manfred Rashack
发明人: Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Stefan Muller , Ernst Baumann , Joachim Rheinheimer , Owe Vogelbacher , Wolfgang Wernet , Liliane Unger , Manfred Rashack
IPC分类号: A61K31/53 , A61K31/513
CPC分类号: C07D495/04 , C07D239/34 , C07D239/48 , C07D239/52 , C07D239/60 , C07D239/70 , C07D239/96 , C07D251/20 , C07D251/26 , C07D251/52 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D491/04 , C07D491/048
摘要: A compound of the formula pharmaceutically acceptable salts and enantiomers thereof and pharmaceutical compositions containing this compound, its pharmaceutically acceptable salts and enantiomers are claimed.
摘要翻译: 本发明要求具有下式的化合物,其药学上可接受的盐和对映异构体以及含有该化合物,其药学上可接受的盐和对映体的药物组合物。
-
公开(公告)号:US06600043B2
公开(公告)日:2003-07-29
申请号:US09748184
申请日:2000-12-27
申请人: Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Stefan Müller , Ernst Baumann , Joachim Rheinheimer , Uwe Josef Vogelbacher , Wolfgang Wernet , Liliane Unger , Manfred Raschack
发明人: Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Stefan Müller , Ernst Baumann , Joachim Rheinheimer , Uwe Josef Vogelbacher , Wolfgang Wernet , Liliane Unger , Manfred Raschack
IPC分类号: C07D23900
CPC分类号: C07D495/04 , C07D239/34 , C07D239/48 , C07D239/52 , C07D239/60 , C07D239/70 , C07D239/96 , C07D251/20 , C07D251/26 , C07D251/52 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D491/04 , C07D491/048
摘要: Carboxylic acid derivatives where R-R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.
摘要翻译: 其中R-R6,X,Y和Z的羧酸衍生物具有说明书中所述的含义及其制备。 新型化合物适用于控制疾病。
-
公开(公告)号:US5932730A
公开(公告)日:1999-08-03
申请号:US809699
申请日:1997-03-27
申请人: Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Stefan Muller , Ernst Baumann , Joachim Rheinheimer , Uwe Josef Vogelbacher , Wolfgang Wernet , Liliane Unger , Manfred Raschack
发明人: Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Stefan Muller , Ernst Baumann , Joachim Rheinheimer , Uwe Josef Vogelbacher , Wolfgang Wernet , Liliane Unger , Manfred Raschack
IPC分类号: C07D251/30 , A61K31/505 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/08 , A61P13/02 , A61P15/00 , A61P25/04 , C07D239/00 , C07D239/26 , C07D239/28 , C07D239/34 , C07D239/38 , C07D239/60 , C07D239/70 , C07D239/96 , C07D251/12 , C07D251/52 , C07D257/02 , C07D309/00 , C07D403/06 , C07D403/12 , C07D405/12 , C07D417/12 , C07D487/04 , C07D491/04 , C07D491/044 , C07D491/048
CPC分类号: C07D495/04 , C07D239/34 , C07D239/48 , C07D239/52 , C07D239/60 , C07D239/70 , C07D239/96 , C07D251/20 , C07D251/26 , C07D251/52 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D491/04 , C07D491/048
摘要: Carboxylic acid derivatives ##STR1## where R-R.sup.6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.
摘要翻译: PCT No.PCT / EP95 / 03963 371日期1997年3月27日 102(e)1997年3月27日PCT PCT 1995年10月7日PCT公布。 公开号WO96 / 11914 PCT 日期:1996年4月25日描述了其中R-R6,X,Y和Z具有说明书所述含义及其制备的羧酸衍生物。 新型化合物适用于控制疾病。
-
公开(公告)号:US5840722A
公开(公告)日:1998-11-24
申请号:US718377
申请日:1996-09-30
申请人: Ernst Baumann , Uwe Josef Vogelbacher , Joachim Rheinheimer , Dagmar Klinge , Hartmut Riechers , Burkhard Kroger , Siegfried Bialojan , Claus Bollschweiler , Wolfgang Wernet , Liliane Unger , Manfred Raschack
发明人: Ernst Baumann , Uwe Josef Vogelbacher , Joachim Rheinheimer , Dagmar Klinge , Hartmut Riechers , Burkhard Kroger , Siegfried Bialojan , Claus Bollschweiler , Wolfgang Wernet , Liliane Unger , Manfred Raschack
IPC分类号: C07D251/26 , A61K31/505 , A61K31/506 , A61K31/53 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/08 , A61P13/02 , A61P15/00 , A61P25/04 , A61P39/02 , C07D239/26 , C07D239/34 , C07D239/38 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , A01N43/66
CPC分类号: A61K31/505 , A61K31/506 , A61K31/53
摘要: A method of inhibiting endothelin receptors by administering to a patient a compound of the formula I ##STR1##
摘要翻译: PCT No.PCT / EP95 / 01099 Sec。 371日期1996年9月30日 102(e)1996年9月30日PCT PCT 1995年3月23日PCT公布。 第WO95 / 26716号公报 日期1995年10月12日一种通过向患者施用式I化合物来抑制内皮素受体的方法
-
78.Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor 有权
标题翻译: 喹啉化合物适用于治疗对血清素-5-HT6受体调节作用的疾病公开(公告)号:US08440694B2
公开(公告)日:2013-05-14
申请号:US13613344
申请日:2012-09-13
申请人: Sean Colm Turner , Wilfried Braje , Andreas Haupt , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Matthias Mayrer , Andrea Hager-Wernet
发明人: Sean Colm Turner , Wilfried Braje , Andreas Haupt , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Matthias Mayrer , Wolfgang Wernet
CPC分类号: C07D487/04 , C07D471/04 , C07D519/00
摘要: The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X′, Y, Q, R1, R2, R3, R4, R5, m, n, p, q, Ra, Rb, X and Ar are as defined in claim 1.
摘要翻译: 本发明涉及式(I)的新颖喹啉化合物及其盐。 该化合物具有有价值的治疗特性,特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。 在式(I)中,R是式(R)的部分,其中*表示与喹啉基的结合位点,其中A,B,X',Y,Q,R 1,R 2,R 3,R 4,R 5, n,p,q,Ra,Rb,X和Ar如权利要求1所定义。
-
公开(公告)号:US20120045524A1
公开(公告)日:2012-02-23
申请号:US13288165
申请日:2011-11-03
IPC分类号: A61K33/24 , A61K31/4745 , A61P35/00 , A61K31/4188
CPC分类号: C07D403/04 , A61K31/41 , A61K31/4164 , A61K41/0038 , A61K45/06 , A61N2005/1098 , A61K2300/00
摘要: The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents.
摘要翻译: 本发明描述了式(I)的苯并咪唑衍生物,其与放射治疗组合或与其它化学治疗剂组合地构成有效的PARP抑制剂。
-
公开(公告)号:US20080280867A1
公开(公告)日:2008-11-13
申请号:US12058478
申请日:2008-03-28
IPC分类号: A61K31/4184 , A61K31/4439 , A61P35/00 , A61K31/454
CPC分类号: A61K31/4184 , A61K31/495 , A61K2300/00
摘要: The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with temozolomide (TMZ).
-
-
-
-
-
-
-
-
-